{
    "clinical_study": {
        "@rank": "31868", 
        "arm_group": [
            {
                "arm_group_label": "Ph 2: LY2157299 + BSC", 
                "arm_group_type": "Experimental", 
                "description": "Phase (ph) 2.  150 milligrams LY2157299 given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles).  Participants will receive best supportive care (BSC) according to institutional guidelines.  Treatment is expected to last for 6 cycles.  Participants may receive additional cycles if they are deriving clinical benefit."
            }, 
            {
                "arm_group_label": "Placebo + BSC", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered orally BID for 14 days followed by 14 days with no study drug  (28 day cycles).  Participants will receive BSC according to institutional guidelines.  Treatment is expected to last for 6 cycles.  Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm."
            }, 
            {
                "arm_group_label": "Ph 3: LY2157299 + BSC", 
                "arm_group_type": "Experimental", 
                "description": "150 milligrams LY2157299 given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of the study drug known as LY2157299\n      on red blood cells in participants with myelodysplastic syndromes (MDS).  Participants with\n      different degrees of disease (very low, low, and intermediate risk) will be studied.  The\n      study treatment is expected to last about 6 months for each participant."
        }, 
        "brief_title": "A Study of LY2157299 in Participants With Myelodysplastic Syndromes", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria\n\n          -  Participants with 5q deletions are allowed only if they have failed or are intolerant\n             of lenalidomide treatment\n\n          -  Participants must have a Revised International Prognostic Scoring System  (IPSS-R)\n             category of very low-, low-, or intermediate-risk disease\n\n          -  In the 8 weeks prior to registration, participants in phase 2 should have anemia with\n             Hb \u226410.0 g/dL (based on the average of 2 baseline measurements and untransfused for\n             at least 1 week) with or without red blood cell (RBC) transfusion dependence\n             confirmed for a minimum of 8 weeks before enrollment\n\n          -  For phase 3, participants should have anemia with RBC transfusion dependence\n             confirmed within 8 weeks before enrollment\n\n          -  Performance status \u22642 on the Eastern Cooperative Oncology Group (ECOG) scale\n\n        Exclusion Criteria:\n\n          -  No history of moderate or severe cardiac disease\n\n          -  No prior history of acute myeloid leukemia  (AML)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008318", 
            "org_study_id": "15242", 
            "secondary_id": [
                "H9H-MC-JBAV", 
                "2013-003235-30"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ph 2: LY2157299 + BSC", 
                    "Ph 3: LY2157299 + BSC"
                ], 
                "description": "Administered orally", 
                "intervention_name": "LY2157299", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + BSC", 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40479"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Jena", 
                        "country": "Germany", 
                        "zip": "07747"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "L\u00fcbeck", 
                        "country": "Germany", 
                        "zip": "23562"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Westerstede", 
                        "country": "Germany", 
                        "zip": "26655"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "zip": "50134"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy", 
                        "zip": "28100"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "zip": "33006"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "zip": "37007"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants with Hematological Improvement (HI) Based on International Working Group (IWG) 2006 Criteria", 
                "safety_issue": "No", 
                "time_frame": "Baseline through HI (24 weeks)"
            }, 
            {
                "measure": "Percentage of Participants who are Transfusion-free or have Hemoglobin (Hb) Increase \u22651.5 Grams/Deciliter (g/dL) Maintained for 8 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline through first 24 weeks of study treatment"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Brief Fatigue Inventory (BFI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 2, Cycle 4, Cycle 6 (Cycle = 28 days)"
            }, 
            {
                "measure": "Change from Baseline in EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L)", 
                "safety_issue": "No", 
                "time_frame": "Phase 3: Baseline, Cycle 2, Cycle 4, Cycle 6 (Cycle = 28 days)"
            }, 
            {
                "measure": "Percentage of Participants with Cytogenetic Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 3, Cycle 6 (Cycle = 28 days)"
            }, 
            {
                "measure": "Resource Utilization: Percentage of Participants who are Hospitalized", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study treatment (24 weeks)"
            }, 
            {
                "measure": "Population Pharmacokinetics: Median Population Clearance of LY2157299", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Predose Cycle 2, 4, 6 (Cycle = 28 days)"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline to date of death from any cause (estimated up to 2 years)"
            }, 
            {
                "measure": "Change from Baseline in Bone Marrow Fibrosis", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 3, Cycle 6 (Cycle = 28 days)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}